G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast

[1]  M. Caron,et al.  Targeting of the Orphan Receptor GPR35 by Pamoic Acid: A Potent Activator of Extracellular Signal-Regulated Kinase and β-Arrestin2 with Antinociceptive Activity , 2010, Molecular Pharmacology.

[2]  J. Stasch,et al.  Kynurenine is an endothelium-derived relaxing factor produced during inflammation , 2010, Nature Medicine.

[3]  H. Pan,et al.  Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain , 2009, Neuropharmacology.

[4]  Gregory J. Hardy,et al.  Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions* , 2009, The Journal of Biological Chemistry.

[5]  Hiroyuki Ohshiro,et al.  GPR35 is a functional receptor in rat dorsal root ganglion neurons. , 2008, Biochemical and biophysical research communications.

[6]  S. Ikeda,et al.  Inhibition of N-Type Calcium Channels by Activation of GPR35, an Orphan Receptor, Heterologously Expressed in Rat Sympathetic Neurons , 2008, Journal of Pharmacology and Experimental Therapeutics.

[7]  C. J. Lee,et al.  Astrocytic control of synaptic NMDA receptors , 2007, The Journal of physiology.

[8]  K. Shinjo,et al.  Zaprinast, a well‐known cyclic guanosine monophosphate‐specific phosphodiesterase inhibitor, is an agonist for GPR35 , 2006, FEBS letters.

[9]  J. Reagan,et al.  Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35* , 2006, Journal of Biological Chemistry.

[10]  Sophie Pezet,et al.  Neurotrophins: mediators and modulators of pain. , 2006, Annual review of neuroscience.

[11]  F. Tarantini,et al.  Kynurenic Acid Inhibits the Release of the Neurotrophic Fibroblast Growth Factor (FGF)-1 and Enhances Proliferation of Glia Cells, in vitro , 2005, Cellular and Molecular Neurobiology.

[12]  V. Vellani,et al.  Functional bradykinin B1 receptors are expressed in nociceptive neurones and are upregulated by the neurotrophin GDNF , 2004, The Journal of physiology.

[13]  R. Schwarcz,et al.  Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities , 2002, Journal of Pharmacology and Experimental Therapeutics.

[14]  E. Meli,et al.  Kynurenine 3‐mono‐oxygenase inhibitors attenuate post‐ischemic neuronal death in organotypic hippocampal slice cultures , 2002, Journal of neurochemistry.

[15]  M. Raiteri,et al.  Presynaptic kynurenate‐sensitive receptors inhibit glutamate release , 2001, The European journal of neuroscience.

[16]  M. Hajós,et al.  Nicotine‐induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid , 2000, Synapse.

[17]  F. Moroni,et al.  Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. , 1999, European journal of pharmacology.

[18]  K. Soliman,et al.  The analgesic effects of tryptophan and its metabolites in the rat. , 1998, Pharmacological research.

[19]  H. Heng,et al.  Discovery of three novel G-protein-coupled receptor genes. , 1998, Genomics.

[20]  V. Kapoor,et al.  Immuno‐localization of kynurenine aminotransferase (KAT) in the rat medulla and spinal cord , 1997, Neuroreport.

[21]  R. Schwarcz,et al.  Characterization of rat brain kynurenine aminotransferases I and II , 1997, Journal of neuroscience research.

[22]  R. Beninger,et al.  Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid , 1997, Neuroscience.

[23]  A. Chiarugi,et al.  Kynurenine Disposition in Blood and Brain of Mice: Effects of Selective Inhibitors of Kynurenine Hydroxylase and of Kynureninase , 1996, Journal of neurochemistry.

[24]  G. Lombardi,et al.  Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities , 1994, Neuroscience.

[25]  G. Lou,et al.  Kynurenic acid distribution into brain and peripheral tissues of mice. , 1994, Canadian journal of physiology and pharmacology.

[26]  G. Lombardi,et al.  Nicotinylalanine Increases the Formation of Kynurenic Acid in the Brain and Antagonizes Convulsions , 1992, Journal of neurochemistry.

[27]  R. Schwarcz,et al.  Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus , 1992, The Journal of comparative neurology.

[28]  M. Beal,et al.  Neuroprotective Effects of L-Kynurenine on Hypoxia—Ischemia and NMDA Lesions in Neonatal Rats , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  M. Beal,et al.  Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain , 1992, Brain Research Bulletin.

[30]  F. Moroni,et al.  Modulation of Quinolinic and Kynurenic Acid Content in the Rat Brain: Effects of Endotoxins and Nicotinylalanine , 1991, Journal of neurochemistry.

[31]  R. Schwarcz,et al.  Two kynurenine aminotransferases in human brain , 1991, Brain Research.

[32]  M. Beal,et al.  Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  F. Moroni,et al.  Quinoxalines interact with the glycine recognition site of NMDA receptors: studies in guinea‐pig myenteric plexus and in rat cortical membranes , 1989, British journal of pharmacology.

[34]  F. Moroni,et al.  Indolpyruvic acid administration increases the brain content of kynurenic acid. Is this a new avenue to modulate excitatory amino acid receptors in vivo? , 1989, Biochemical pharmacology.

[35]  R. Schwarcz,et al.  High-affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  F. Moroni,et al.  Glycine and kynurenate modulate the glutamate receptors in the myenteric plexus and in cortical membranes. , 1989, European journal of pharmacology.

[37]  G. Lombardi,et al.  Kynurenic acid is present in the rat brain and its content increases during development and aging processes , 1988, Neuroscience Letters.

[38]  G. Lombardi,et al.  Presence of Kynurenic Acid in the Mammalian Brain , 1988, Journal of neurochemistry.

[39]  R. Schwarcz,et al.  Identification and quantification of kynurenic acid in human brain tissue , 1988, Brain Research.

[40]  F. Moroni,et al.  Biochemical and behavioural studies on indole-pyruvic acid: a keto-analogue of tryptophan. , 1987, Pharmacological research communications.

[41]  R. Schwarcz,et al.  Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.

[42]  I. Lapin.  Depressor effect of kynurenine and its metabolites in rats. , 1976, Life sciences.

[43]  H. Collier,et al.  The abdominal constriction response and its suppression by analgesic drugs in the mouse. , 1968, British journal of pharmacology and chemotherapy.

[44]  I. Lapin.  Experimental studies on kynurenines as neuroactive tryptophan metabolites: past, present and future , 1980 .